Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.
The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.
Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback